The FDA approved Datroway to treat metastatic or unresectable HR+/HER2- breast cancer in people who have tried standard chemo ...
Welcome, ladies and gentlemen, to AstraZeneca's full-year and Q4 2024 results conference call for investors and analysts.
Seeking Alpha on MSN11h
AstraZeneca outlines $3.2 dividend hike and anticipates strong 2025 growthOncology revenue reached $22.4 billion in 2024, with Tagrisso, Lynparza, and Enhertu delivering strong growth. Enhertu's revenue grew 54% in Q4, supported by expanded indications, including HER2 low ...
After 2024, which saw a steady recovery by the life sciences industry, it looks like 2025 is set to be a year of change and ...
A pharma industry group asked the FDA to "take action" against a "dangerous" ad Hims & Hers plans to run during the Super Bowl ...
If the trial is successful, the firm's complete estrogen receptor antagonist would complement its other biomarker-driven breast cancer assets.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback